HOME >> BIOLOGY >> NEWS
International study findings link acne-like rash to effectiveness of new targeted cancer treatment

Geneva, Switzerland: Acne is not a condition that anyone would welcome under normal circumstances, but an international study of a new targeted cancer treatment cetuximab has shown that patients who developed an acne-like rash responded better to the treatment than those who did not.

Professor Eric Van Cutsem told a news briefing today (Thursday 30 September) at the EORTC-NCI-AACR[1] Symposium on Molecular Targets and Cancer Therapeutics that a trial, conducted in Belgium and the USA, had demonstrated that the more severe the rash the better the patients' tumours had responded to the treatment and the longer was their median survival.

Professor Van Cutsem, who is head of the Digestive Oncology Unit and Professor of Medicine at University Hospital Gasthuisberg in Leuven, said 346 patients with advanced colorectal cancer were treated in the study in Leuven and other Belgian and U.S. centres.

All the patients had metastatic cancer and had failed to respond to at least two prior chemotherapy regimens, although all still had a reasonable quality of life, either being fully active or at least still able to carry out light work.

Cetuximab, also known as Erbitux, is a new targeted treatment a monoclonal antibody designed to home in selectively on a protein called the epidermal growth factor (EGFR). EGFR is found on the surface of some cells and plays a role in regulating cell growth. Cetuximab interferes with the growth of cancer cells by binding to EGFR. It is approved by the Food and Drug Administration in the USA for use with the cancer drug irinotecan for colorectal cancer that has failed other treatments. It is also the first monoclonal antibody targeting EGFR to have gained marketing authorisation in Europe and is now being evaluated in first-line treatment of colorectal cancer, with promising results.

Professor Van Cutsem said that the acne-like rash was also a side effect of other EGFR inhibitors but it was not
'"/>

Contact: Margaret Willson
m.willson@mwcommunications.org.uk
41-227-612-205
European Organisation for Research and Treatment of Cancer
30-Sep-2004


Page: 1 2

Related biology news :

1. USAID, Conservation International & Starbucks launch Conservation Coffee Alliance in Central America
2. ConocoPhillips & Conservation International launch Biodiversity Action Plan in Venezuela
3. A room with a view for the International Space Station: Completion of the cupola observation module
4. International symposium on nutritional genomics
5. First International Scientific Conference on Childhood Leukaemia
6. 1st International Conference on Cell Therapy for Cardiovascular Disease
7. International research conferences at the Villa Vigoni
8. Conservation International & SC Johnson invest in Ecuadors rainforest to offset climate impacts
9. STN International launches Derwent World Patents Index First View
10. Media invited to attend International Society For Heart & Lung Transplantation meeting April 21-24
11. International critical care doctors release first-ever guidelines for sepsis

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/17/2019)... ... 16, 2019 , ... At nearly eleven years old, Seve, a white Golden ... owner, in the last year or so, he was a little “gimpy” and occasionally ... Echevarria of VCA University Animal Hospital in Dallas, diagnosed him with severe ...
(Date:7/9/2019)... , ... July 09, 2019 , ... ... Tx Genetic Research into its incubator program. The founder and CEO of Tx ... improve the lives of those suffering from epithelial connective tissue disorders. , “We ...
(Date:6/27/2019)... ... June 27, 2019 , ... Lighting designers from integrated design firm ... which honored the designers for creating both engaging and energy efficient lighting systems. , ... an office tower in San Diego, California earned an IES Illumination Award of Merit ...
Breaking Biology News(10 mins):
(Date:5/31/2019)... NEWPORT BEACH, Calif. (PRWEB) , ... May 30, ... ... the future of neurotoxins, is pleased to announce the strategic acquisition of Metabiologics, ... for research. The acquisition provides Object exclusive ownership and commercialization rights to a ...
(Date:5/15/2019)... ... May 15, 2019 , ... Milton Hershey School® has named William ... work within the biomedical industry, where he is changing lives by creating solutions to ... “William Harding epitomizes the vision of our founders – Milton and Catherine Hershey – ...
(Date:5/8/2019)... ... 2019 , ... Standing at 16.2 hands, Atlas is on the large side for a Quarter ... barrel racing, among other activities. When loping around a corner in late 2017, Atlas ... busy horse to only being able to walk. Fortunately Atlas’ owner, Kelly, sought the ...
(Date:5/2/2019)... ... April 30, 2019 , ... ... standard, REPROCELL USA Inc. has demonstrated its ability to provide various services ... aims to enhance customer satisfaction through the effective implementation of its quality ...
Breaking Biology Technology:
Cached News: